Weight care · Notify list
Retatrutide is not available yet.
Retatrutide is an investigational Lilly medicine. It is not FDA-approved. Lilly has said it plans to file for approval in the first quarter of 2027. We will not prescribe or sell it before it is approved, and we do not have a price.
What it is, honestly
Retatrutide is a triple agonist (GLP-1, GIP and glucagon receptors) still in clinical development. It is sometimes talked about as if it uniquely preserves muscle during weight loss. A DXA substudy of retatrutide did not show that the share of weight lost as lean mass was different from other obesity medicines in a way that would make it “muscle-sparing.” The drugs that have been studied specifically to protect muscle in this setting (including bimagrumab with a GLP-1, and enobosarm) are also not approved for sale.
What we can offer now is FDA-approved GLP-1 care — including the Wegovy pill and Foundayo — plus a muscle-protection plan (protein, resistance training 2–3 days a week, and follow-up). A November 9, 2026 Nature Medicine trial found that adding three weekly resistance-training sessions to tirzepatide reduced lean soft-tissue loss from 4.67 kg to 3.57 kg and increased strength (Green et al.).
This page is information, not an offer to sell retatrutide and not a prediction of FDA approval or of a future price.
Notify me if it becomes available
Sources
- Lilly: Retatrutide clinical development (read Nov 2026)
- Green DJ et al. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity. Nat Med. Published 9 Nov 2026.
This page is general information, not medical advice.
Last updated .